[Combination of XXXX and @entity900 in the treatment of advanced @entity1149 ].

@entity1 @entity137 @entity932 @entity882 @entity1149 @entity900 @entity1431 @entity236 @entity1205
BACKGROUND: To evaluate the efficacy and @entity137 of the combination of @entity1205 and @entity900 in the treatment of @entity1 with advanced @entity1149 ( @entity1149 ). METHODS: Forty @entity1 with locally advanced (stage III) or metastatic (stage IV) @entity1149 were enrolled into the study. The @entity1 received @entity1205 75 mg/m   on day 1, and @entity900 75-80 mg/m   on day 1 or days devided into 1-3 of a 21-day cycle. Each @entity1 should complete two cycles. RESULTS: An objective response rate was obtained in 43.6% of 39 @entity1 (one complete and 16 partial response), whereas 15 @entity1 had stable disease and 7 @entity1 were progressive. The response rate was 44.4% (8/18) in the initial @entity1 , and 42.9% (9/21) in the retreated @entity1 . No significant difference existed between the two groups (P > 0.05). The main @entity137 were @entity1431 (17.5% in grade III+IV) and @entity882 (12.5% in grade III+IV). One @entity1 died of @entity932 . CONCLUSIONS: The combination of @entity1205 and @entity900 is a feasible, well-tolerated and active scheme in the first-line or second-line treatment of advanced @entity1149 . Great attention must be paid to the possible severe @entity236 of the regimen.
